---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281807"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:49:33.711119+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026

## Summary
- Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.
- R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.
- Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.
- FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.
- Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026.

## SEC filing metadata
- accession: 0001193125-25-281807
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/0001193125-25-281807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/d77724d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281807
- JSON: https://secwatch.observer/filing/0001193125-25-281807.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.